Hormonal
Weekly tirzepatide injections combined with dietician support reduce OSA severity by approximately 50% in obese patients with moderate to severe OSA.
If you are obese and have moderate to severe sleep apnea, ask your doctor about tirzepatide. This weekly injection, combined with dietary support, has been shown to cut your apnea severity in half. It is FDA-cleared for this use and may improve your blood pressure and sleep quality, though you should expect some mild stomach issues initially.
Obese people with moderate to severe OSA (~ 50 events/hour sleep group average), half of whom were regular CPAP users, randomised to weekly tirzepatide injections plus dietician support, had ~50% reductions in OSA severity versus baseline [92].
Why this rating
Based on a large-scale randomized trial (SURMOUNT-OSA) with clear secondary outcomes.
Source
Developments in Pharmacotherapy for Obstructive Sleep Apnoea: Unlocking the Potential for Targeted Treatment
Danny J. Eckert · Drugs · 2025
DOI 10.1007/s40265-025-02268-9
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →